Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.

por Raynaud, F. I., Odell, D. E., Kelland, L. R.
Publicado 1996

Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs

por Cummings, J, Raynaud, F, Jones, L, Sugar, R, Dive, C
Publicado 2010

Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance.

por Judson, I., Briasoulis, E., Raynaud, F., Hanwell, J., Berry, C., Lacey, H.
Publicado 1997

Intercellular ultrafast Ca(2+) wave in vascular smooth muscle cells: numerical and experimental study

por Quijano, J. C., Raynaud, F., Nguyen, D., Piacentini, N., Meister, J. J.
Publicado 2016

A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)

por Beale, P, Judson, I, O'Donnell, A, Trigo, J, Rees, C, Raynaud, F, Turner, A, Simmons, L, Etterley, L
Publicado 2003

A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies

por Benepal, T, Jackman, A, Pyle, L, Bate, S, Hardcastle, A, Aherne, W, Mitchell, F, Simmons, L, Ruddle, R, Raynaud, F, Gore, M
Publicado 2005

Hormonal impact of the 17α-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

por O'Donnell, A, Judson, I, Dowsett, M, Raynaud, F, Dearnaley, D, Mason, M, Harland, S, Robbins, A, Halbert, G, Nutley, B, Jarman, M
Publicado 2004

Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors

por Shuttleworth, S.J, Silva, F.A, Cecil, A.R.L, Tomassi, C.D, Hill, T.J, Raynaud, F.I, Clarke, P.A, Workman, P
Publicado 2011

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026

por Nutley, B P, Smith, N F, Hayes, A, Kelland, L R, Brunton, L, Golding, B T, Smith, G C M, Martin, N M B, Workman, P, Raynaud, F I
Publicado 2005

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

por O'Donnell, A, Padhani, A, Hayes, C, Kakkar, A J, Leach, M, Trigo, J M, Scurr, M, Raynaud, F, Phillips, S, Aherne, W, Hardcastle, A, Workman, P, Hannah, A, Judson, I
Publicado 2005

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

por Benson, C, White, J, Bono, J De, O'Donnell, A, Raynaud, F, Cruickshank, C, McGrath, H, Walton, M, Workman, P, Kaye, S, Cassidy, J, Gianella-Borradori, A, Judson, I, Twelves, C
Publicado 2007

A phase I study of the nitroimidazole hypoxia marker SR4554 using (19)F magnetic resonance spectroscopy

por Lee, C P, Payne, G S, Oregioni, A, Ruddle, R, Tan, S, Raynaud, F I, Eaton, D, Campbell, M J, Cross, K, Halbert, G, Tracy, M, McNamara, J, Seddon, B, Leach, M O, Workman, P, Judson, I
Publicado 2009

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

por Kolinsky, M.P., Rescigno, P., Bianchini, D., Zafeiriou, Z., Mehra, N., Mateo, J., Michalarea, V., Riisnaes, R., Crespo, M., Figueiredo, I., Miranda, S., Nava Rodrigues, D., Flohr, P., Tunariu, N., Banerji, U., Ruddle, R., Sharp, A., Welti, J., Lambros, M., Carreira, S., Raynaud, F.I., Swales, K.E., Plymate, S., Luo, J., Tovey, H., Porta, N., Slade, R., Leonard, L., Hall, E., de Bono, J.S.
Publicado 2020

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

por Basu, B, Krebs, M G, Sundar, R, Wilson, R H, Spicer, J, Jones, R, Brada, M, Talbot, D C, Steele, N, Ingles Garces, A H, Brugger, W, Harrington, E A, Evans, J, Hall, E, Tovey, H, de Oliveira, F M, Carreira, S, Swales, K, Ruddle, R, Raynaud, F I, Purchase, B, Dawes, J C, Parmar, M, Turner, A J, Tunariu, N, Banerjee, S, de Bono, J S, Banerji, U
Publicado 2018